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Dear Prof. Knottnerus,
Dear Prof. Tugwell,
Accompanying this letter, please find our manuscript with the title “GRADE Guideline: Rating the certainty 
in time-to-event outcomes – Study limitations due to censoring of participants with missing data in 
intervention studies” for publication as part of the GRADE Guidelines series in the Journal of Clinical 
Epidemiology. 
The article presents a guidance that aims to assist systematic review and guideline authors with the 
identification and assement of potiential bias introduced by informative censoring in the analyses of time-
to-event outcomes. Furthermore, it discusses the incorporation of the results of such assessments into the 
GRADE approach. It was developed by the GRADE time-to-event project group and approved by the 
GRADE working group and the GRADE guidance group.
The guidance builds on previous articles that were developed within the GRADE time-to-event project group 
and published in the Journal of Clinical Epidemiology. This includes a methodological systematic review 
where we identified serious diffiuclties of systematic review authors in the calculation and presentation of 
time-to-event outcomes. Unpublished results have shown that only a minor proportion of authors are aware 
of potential bias introduced by informative censoring. These findings were confirmed in a survey that 
authors of this manuscript performed among the editorial straff of multiple Cochrane review groups. 
As part of our own daily engagement in systematic reviews as editors, authors, and contributors to 
Cochrane and the GRADE working group, we have seen the urgent need for a guidance to raise awareness 
to potential study limitations that are distinct for time-to-event outcomes and their analyes. 
We believe that our guidance will be well placed in the Journal of Clinical Epidemiology given its established 
evidence-based and methodological profile and ensure that our manuscript and the submitted materials 
have not been published and are not under consideration for publication elsewhere.
Thank you very much for your consideration.
Yours sincerely,
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Response to reviewers
Comments from the editors and reviewers:
-Reviewer 1
The authors provide GRADE guidance for the consideration of study limitations (risk of bias) 
due to missing participant outcome data for time-to-event outcomes in intervention studies. 
The article is well written and very clear. I have only one major comment to improve the 
current manuscript.
We thank the reviewer for his thoughtful and elaborate comment that substantially 
improved the manuscript. In order to comply with the comments, we have 
reconstructed individual participant level data from our example 1 and performed the 
analyses as suggested by the reviewer.
Furthermore, we have adapted the manuscript on several segments to increase its 
clarity. All additional changes are marked in the “Revised Manuscript with Changes 
Marked” file. These changes did neither alter the content nor the structure of the 
article. We sincerely hope that our additional changes are in line with the peer 
reviewer’s ideas.
The authors often claim that the risk of bias due to missing participant outcome data for time-
to-event outcomes in intervention studies can be severe. They discuss two examples. I would 
recommend to apply the technique by Guyot P et al. (Enhanced secondary analysis of survival 
data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res 
Methodol. 2012; 12: 9) to one of these examples. With this method, one is able to receive 
individual data. Then, one could mimic the situation which is discussed here (page 15):
 “Where the distribution of individuals lost to follow-up over-time unquestionably differs 
between the arms, for example a high number of early censoring in one arm versus late 
censoring in the other arm, this may indicate the dependence of these censoring events. 
Differences in early censoring are especially relevant here because they can, in most 
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situations, be more easily associated with missing follow-up data than “end-of study 
censoring”.”
In example 1 (figure 2), I would suggest to classify the early censored data within 7 days (as 
marked in figure) as “missing participant outcome data”. And then apply the procedure as 
proposed by the authors and provide a demonstration of “5. How censoring participants with 
missing follow-up data may affect the results of the Study.”  This would be pragmatic and 
convincing.
A recent example of this method is also given here: Lambert, J et al. Infectious disease 
consultation for candidaemia.  The Lancet Infectious Diseases, 2020, Volume 20, Issue 2, 164 
– 165
Again, we want to thank the peer reviewer for suggesting the approach, which we 
gladly followed. Given the clarity of the survival curve for example 1, we were able to 
reconstruct outcome event and censoring time points directly from the available 
survival curve. We compared the hazard ratio and confidence intervals resulting from 
our directly reconstructed dataset with the hazard ratio and confidence intervals 
calculated for a dataset we reconstructed following the approach by Guyot et al. and 
found a closer correspondence to the original estimates with our manually extracted 
data. Furthermore, since the approach by Guyot et al. assumes independent censoring, 
we found that an extraction where we were able to include the majority of censoring 
time points without further assumption is preferable for our cause. For these reasons, 
we finally chose the manually extracted dataset for the imputations suggested by the 
reviewer. In accordance with the reviewer’s suggestion we then imputed events for all 
participants which were censored prior to seven months in order to illustrate the 
uncertainty that is added by early censoring to survival analyses. We included a 
scenario to the manuscript where all participants censored within the first seven 
months of follow-up experience the event of interest one month after the censoring 
time-point. We sincerely hope that our approach and the resulting changes to our 
manuscript comply with the reviewer’s ideas. 
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The following sections have been added to the manuscript and the appendix to comply 
with the reviewer’s suggestions: 
5.3. Illustration of the uncertainty introduced through early dependent censoring to 
comparisons 
In order to illustrate the impact of early depended censoring on survival analyses, we 
reconstructed individual participant data from the analysis of overall survival in a 
study by Denis et al. (32) (see also section 6.1). In this study example the number of 
censored participants was different between the groups, particularly in the beginning 
of follow-up. Given the transparent reporting of outcome and censoring events in the 
available survival curve (Figure 2), we were able to reconstruct event and censoring 
time points for the individuals in each group (see Appendix A3). Box 1 provides a 
detailed description of the study example and Appendix A3 provides a summary of our 
proceeding to reconstruct survival data. We verified the consistency of our 
reconstructed dataset with the approach presented by Guyot et al. (33), that allows 
recreating individual participant level data from published survival curves, and 
recalculated hazard ratios and Kaplan-Meier survival curves. 
To demonstrate the impact of early censoring on results, we considered a hypothetical 
scenario in which all participants who were censored prior to seven months of follow-
up experience the event one month after censoring, i.e. these data are no longer 
censored but are counted as events. This assumption represents the extreme case of a 
very large positive correlation between early censoring and the experience of the 
event of interest. 
Appendix A4 figures 1 and 2 show the Kaplan-Meier survival curves for the 
reconstructed dataset and the hypothetical scenario. The original hazard ratio 
resulting from the authors’ analysis is 0.32 (95% confidence interval (CI) 0.15 to 
0.67). The hazard ratio resulting for the data we reconstructed from the published 
survival curve was 0.32 (95% CI 0.15 to 0.65) showing that our reconstructed data set 
is nearly identical to the original one. The original analysis indicates a substantial 
GRADE Guideline 29:
Rating the certainty in time-to-event outcomes – Study limitations due to censoring of participants 
with missing data in intervention studies
4
survival advantage for participants in the experimental arm under the questionable 
assumption of independent censoring. 
Appendix A4 figures 1 and 2 illustrate that a positive correlation between early 
censoring and the experience of the event of interest leads to an overestimation of the 
survival probability in both study arms. As more participants in the intervention arm 
are censored prior to seven months compared to the control arm (26 participants 
versus 19 participants), the hazard ratio increases to 0.69 (95% CI 0.44 to 1.07) in the 
hypothetical scenario. This illustrates that the effect estimation is biased if there is a 
positive correlation between early censoring and the experience of the event of interest 
and additionally a higher proportion of censored participants in the intervention arm. 
Therefore, there is a loss of certainty in the results of survival analyses in the case of 
substantial censoring, particularly throughout the early periods of follow-up and 
where no information is available on the reasons for censoring.
Appendix A3. Reconstruction of survival data to illustrate the impact of early 
dependent censoring
To illustrate the impact of early dependent censoring on comparisons, we 
reconstructed individual participant data from the survival curves published for the 
analysis of overall survival in the article by Denis et al. (32). The study shows an 
unbalanced number of censored participants particularly during early follow-up, with 
more censored participants in the intervention arm compared to the control arm. 
Given the clear reporting in the survival curves, we were able to reconstruct outcome 
event and censoring time points for the individuals in each of the compared groups. 
We verified our proceeding with the algorithm presented Guyot et al. (33) that allows 
to reconstruct individual participant level data from published survival curves. The 
algorithm attributes a constant rate of censoring to intervals in between outcome 
events and time-points for which a number of individuals at risk is reported. It 
therefore works optimal assuming independent censoring. Under the objective of our 
illustration, we decided not to directly use the dataset resulting from the algorithm 
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proposed by Guyot and colleagues but to work with individual patient data that we 
reconstructed directly from the published survival curve. Nevertheless, we used the 
data set produced under application of the algorithm to confirm the consistency of our 
manually extracted data by comparing the data points retrieved through both 
approaches. 
We extracted data with the software DigitizeIt (www.digitizeit.de), which allows to 
assign each point on the survival curve a corresponding time-point on the x-axis. We 
marked all declines of the curve as outcome event and all crosses as censoring time-
points. The reported curve for the experimental arm was unclear for two censoring 
events in the first interval (0 to 5 months) and the last interval (over 15 months) 
respectively, which were not directly identifiable on the curve, but must have occurred 
in these intervals as indicated by the number of individuals at risk. Similarly, for the 
curve representing survival in the control arm, two censoring events were not 
identifiable within the first interval (0 to 5 months). For all scenarios we assumed the 
missing censoring events to have happened on the last possible time-point of this 
interval (4.99 and 18.99 months). In the so retrieved dataset, we modified the survival 
data of participants censored within the first seven months of follow-up to illustrate 
the impact of early dependent censoring. We present a hypothetical scenario where all 
participants censored prior to seven months of follow-up experience the outcome event 
one month after the original censoring. Subsequently, we calculated hazard ratios 
with the Cox proportional hazards model and present Kaplan-Meier survival curves. 
All statistical analyses were performed using the software R (56). We want to point out 
that our imputation does not claim to compare a difference in treatment effects, but to 
illustrate the loss of certainty that is introduced to survival analyses through a high 
degree of censoring particularly during the early period of follow-up.
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Appendix-figure 1: Kaplan-Meier survival curves calculated from the individual 
participant level data reconstructed from the analysis of overall survival in Denis et 
al. (32). (figures in higher resolution are included in the submitted manuscript file)
GRADE Guideline 29:
Rating the certainty in time-to-event outcomes – Study limitations due to censoring of participants 
with missing data in intervention studies
7
Appendix-figure 2: Kaplan-Meier survival curve calculated from the individual 
participant level data reconstructed from the analysis of overall survival in Denis et 
al. (32). Participants who were censored prior to seven months of follow-up in both 
study arms were set to experience the outcome event one month after original 
censoring. (figures in higher resolution are included in the submitted manuscript file)
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Objective: To provide Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE) guidance for the consideration of study limitations (risk of bias) due to 
missing participant outcome data for time-to-event outcomes in intervention studies.
Study Design and Setting: We developed this guidance through an iterative process that 
included membership consultation, feedback, presentation and iterative discussion at meetings 
of the GRADE Working Group.
Results: The GRADE working group has published guidance on how to account for missing 
participant outcome data in binary and continuous outcomes. When analysing time-to-event 
outcomes (e.g. overall survival, time-to-treatment failure) data of participants for whom the 
outcome of interest (e.g. death, relapse) has not been observed are dealt with through 
censoring. To do so, standard methods require that censored individuals are representative for 
those remaining in the study. Two types of censoring can be distinguished, end of study 
censoring and censoring because of missing data, commonly named loss to follow-up 
censoring. However, both types are not distinguishable with the usual information on 
censoring available to review authors. Dealing with individuals for whom data is missing 
during follow-up in the same way as individuals for whom full follow-up is available at the 
end of the study increases the risk of bias. Considerable differences in the treatment arms in 
the distribution of censoring over time (early versus late censoring), the overall degree of 
missing follow-up data and the reasons why individuals were lost to follow-up may reduce the 
certainty in study results. With often only very limited data available, review and guideline 
authors are required to make transparent and well-considered judgements when judging risk 
of bias of individual studies and then come to an overall grading decision for the entire body 
of evidence. 
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Conclusion: Concern for risk of bias resulting from censoring of participants for whom 
follow-up data is missing in the underlying studies of a body of evidence can be expressed in 
the study limitations (risk of bias) domain of the GRADE approach.
Keywords
GRADE; Certainty of the evidence; Time-to-event outcomes; Survival analysis; Risk of bias; 




 Analysis methods for time-to-event outcomes deal with participants for whom 
outcome data is unavailable through censoring. Two types of censoring, end of study 
censoring and censoring because of missing data (commonly named loss to follow-up 
censoring), have to be differentiated.
 Censoring of individuals with missing follow-up data mayis likely to violate the 
assumption of independence of censoring and increases the risk forof biased results.
 The magnitude of bias resulting from censoring of participants with missing data 
depends on several factors. An increasing degree of dependent censored observations 
and difference among the study arms, increases the risk of biased resultsbias.
What are the implications and what should be changed?
 Often the, reasons why individuals in studies were censored and the time-points of 
censoring are not availableunavailable to systematic review and guideline authors. 
Systematic review and guideline authors who therefore have to make risk of bias 
judgements for primary studies based on the distribution of censoring over time or the 
degree and reasonsof missing participant follow-up data is missing.
 Systematic review and guideline authors need to make GRADE judgements across the 
body of evidence for study limitations resulting from censoring of participants with 
missing data considering all available information, including the possibility of 
carrying out sensitivity analysesanalysis by temporarily removing studies 
withassessing whether studies at high risk of bias or studies wherein which there are 
some concerns yield different results.
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1. Introduction:
The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
working group has defined domains that can limit the certainty in a body of evidence (1-6). 
Within its study limitations domain (i.e., risk of bias), the GRADE approach has issued 
guidance on how to account for missing participant outcome data for binary and continuous 
outcomes (6, 7). That guidance proposes conducting sensitivity meta-analyses making 
assumptions about the outcomes of participants with missing data, to test the robustness of the 
findings of the primary meta-analysis (7, 8). 
WhileAlthough the basic principles for the assessment of aassessing risk of bias associated 
with missing participant outcome data in binary outcome analysis are applicablealso apply to 
time-to-event analysis as well, there are certain conceptual discrepancies that result in a 
different assessment and detection of a potential bias inissues uniquely applicable to time-to-
event outcomes. In contrast to binary data analysis, time-to-event studies, which assess not 
only whether an event of interest occurs, but also the time taken for that event to occurwhen it 
occurs, typically follow patients for varying periods of time. Because time-to-event analyses 
allow to include data from individuals with variable lengths of follow-up, those for whom 
follow-up data becomes absent during the study interval are typically treated in the same way 
as those with regular follow-up until the end of the analysis (i.e. they provided complete data). 
Therefore, we here refer to missing follow-up data to describe thatcharacterize the situation 
when information for an individual becomes absent at a time -point within the intended and 
pre-specified observation period. This article discusses GRADE rating of study limitations 
associated with missing follow-up data when dealing with time-to-event analysis.
2. Background
2.1. Time-to-event analysis and censoring
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Time-to-event analysis is also often referred to as survival analysis, in which the “survival 
time” describes the time until an event such as death occurs. The most prominent methods to 
analyse time-to-event outcomes include Kaplan-Meier curves along with the log-rank test and 
the Cox proportional hazards regression model (9, 10). Time-to-event outcomes are often 
described by survival rates, defined as the probability that an individual will not have 
experienced an event (e.g. “survived”) up to a certain time point, or hazard rates, which can 
be interpreted as instantaneous failure rates, meaning an individual’s likelihood of 
experiencing an event (e.g. “death”) at a certain time point given that the event has not 
occurred up to this time point. 
The most prominently applied relative effect measure is the hazard ratio, which is the ratio of 
hazards between two groups. It is commonly obtained from the Cox proportional hazards 
regression model, which adjusts for relevant covariates and confounders. A univariateAn 
unadjusted hazard ratio can also be derived indirectly using other analytical techniques, like 
the Kaplan-Meier method or the log-rank test (10, 11). 
A core feature of time-to-event analysis is the consideration of “censoring” which occurs 
when a particular patient completes his/herpatients complete their follow-up period without 
having experienced the event of interest. Censored observations are included in analyses to 
optimize the efficiency that time-to-event analysis provides over simple binary data analysis 
(12)(12). If the time to an event and censoring are not included in the calculation of the (log) 
hazard ratio, it equals the (log) relative risk. 
To include censored observations in time-to-event analyses, general methods of survival 
analysis require an assumption of non-informative and independent censoring. Violations of 
this assumption introduce risk of bias. For interested readers we provideAppendix A1 
provides a short review of the definition of non-informative censoring and its relation to 
independent censoring in the appendix (Appendix A.1).. In accordance with established 
9
training resources for time-to-event analysts (13)(13), we will use the concept of independent 
and dependent censoring to describe situations under which censoring may lead to distortion 
of analysis results.
Independent censoring assumes thatoccurs when censored participants and those remaining 
under observation have the same probability of experiencing the event of interest, as if the 
censored individuals were “randomly drawn” during the course of follow-up (13, 14)(13, 14). 
An example for censoring mechanisms independent from the survival time (and also non-
informative) is administrational closure of a study. Differences in the observation times of 
participants then are solely a result of the staggered study entry times and the fixed study 
closure time as visible in (figure 1) (13, 15).
Figure 1: Types of censoring: For participant 1 the occurrence of the outcome event is 
observable. Participants 2 and 3 are censored because of the administrational closure of the 
study. The variation in their duration of follow-up and the differing censoring time- points result 
from the staggered recruiting phase of the study. Participant 4 is lost from the observation 
before the administrational ending of the study and censored for a different reason. 
When individuals are censored because of missing follow-up data, this assumption is likely to 
be violated. Examples of such situations which may bias results include:
 Participants withdraw consent due to physical or mental side effects of an 
intervention;
 Participants are withdrawn from the observation and censored following switching 
treatment as a result of progressive disease;
 Investigators fail to locate study participants.
2.2. Reporting of time-to-event data and censoring in primary studies
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The overallFlaws in reporting of time-to-event analyses may be particularly flawed, which 
complicatescomplicate their adequate appraisal by systematic review authors including the 
assessment of aassessing risk of bias resulting from censoring of individuals with missing 
follow-up data (16-19). InsufficientSuboptimal reporting relatesincludes but is not limited to 
outcome definitions, the extent and duration of follow-up, precision measures such as the 
number of participants at risk at certain time points, and details of statistical model building. 
Precise definitions ofAuthors often fail to precisely define censoring mechanisms and, omit 
the number of censored participants are likewise often omitted and it is often not known, and 
fail to state why individual study participants were censored (16-19). 
Other methodological research has shown that even studiesStudies published in leading 
medical journals are not immune to reporting errors aslimitations: for instance, one 
methodological study found inconsistency between the number of participants reported in the 
text/tables as ‘lost before the end of the study’ and those assessed from Kaplan-Meier curves 
(20)(20). Prior work has specified minimal reporting items for time-to-event analyses and 
survival curves (17, 18, 21, 22). Appendix A.2A2 outlines specific reporting requirements that 
allow systematic review and guideline authors to assess the suitabilitypossible risk of bias 
resulting from informative censoring. 
3. Methods
This guidance was developed by members of the GRADE working group. They included 
methodologists, clinical epidemiologists and biostatisticians with experience in systematic 
reviews and/or guideline development. The group developed the guidance based on iterative 
discussions by email, on conference calls and at a GRADE working group meeting in 
Manchester, UK, in October 2018. The final draft of the guidance was presented during the 
GRADE working group meeting in Hamilton in June 2019 and was approved following the 
group’s standard approval process.
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4. Scope
This guidance aims to support systematic review and guideline authors in the assessment of 
the study limitations (risk of bias) due to missing follow-up data for time-to-event outcomes 
in intervention studies. Therefore, we hereWe describe an approach to the issue fromthat takes 
a systematic reviewer perspective that reliesrelying on information that one could typically 
obtain from only the trial report and its accompanying records only. To comply with well-
known resources for systematic review authors to assess the risk of bias in individual studies 
and with reference to previous GRADE guidance for rating the certainty of the evidence with 
focus on study limitations (risk of bias), we refer to missing follow-up data as the 
unavailability of follow-up data for individuals during the study interval (6, 23, 24). This 
includes all types of missing data and situations in which the outcome status of study 
participants becomes unavailable during the study period irrespective of the reason (e.g., 
patients not available or inappropriately excluded) (24, 25).(25, 26). 
The concerning risk of bias arises, for example, when investigators censor individuals for 
whom data is missing dependently and include them in the computation of effect measures in 
the same way as participants with independent censoring (e.g., those whose follow-up ended 
appropriately at the end of the data collection period). Systematic review and guideline 
authors seldom have the possibility of knowinginformation regarding the reasons for 
censoring for each participant in every eligible study. Consistent with well-known instructions 
for systematic review authors, we therefore provide guidance that is primarily aimed at 
detecting a potential bias in individual studies (23). Judgements on study level are then used 
to inform the risk of bias assessment for an overall body of evidence for one specific(23, 24). 
Judgements on study level then inform the risk of bias assessment for an overall body of 
evidence separately for each outcome.
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In accordance with the previous GRADE guideline for missing participant outcome data for 
binary and continuous outcomes, we giveprovide guidance for systematic review and 
guideline authors who assess comparative clinical trials based on aggregated data (7)(7). 
Similar to this guideline weWe differentiate the issue of adequately accounting for loss to 
follow-up from that of adherence to the intention to treat (ITT) principle, which relates to 
analyzing study participants with known data in the groups to which they were allocated (7, 
2627). 
We focus on risk of bias in the outputs of the “standard” methods of survival analysis and the 
Cox model hazard ratio as the single comparative relative effect size measure (16-19). Within 
the context of this guidance we assume that the primary study investigators and subsequently 
the authors of meta-analyses have chosen the correct method for analysing competing events 
for the intended research question.
5. How censoring participants with missing follow-up data may affect the results of the 
study
5.1. Censoring of participants leading to over- and under estimation of the survival probability
Similar to binary outcome analysis, the distortion of the outcome probability of the group 
under study depends on the outcome probability of those for whom data is missing. In case 
data forWhen individuals who are more likely to experience the (negative) event of interest 
(e.g.,. death) are also more likely to be missing (positive correlation between the occurrence 
of the event and missingness of data), e.g. because they are more likely to be lost to follow-
up, the true survival probability of a study group will inevitably be overestimated (12, 23). 
This means that the corresponding true risk of the (negative) event occurrence will be 
underestimated. Such an association may occur, for example, if participants with treatment-
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related adverse events are no longer followed-up and are censored at the time of loss to 
follow-up. 
On the other hand, in case of a negative correlation between the occurrence of the event and 
the probability of being censored, the true survival probability for a study group may be 
underestimated (and the corresponding true event risk overestimated) (23)(23). AnFor 
example for this situation might happen, underestimation of the event-free survival 
probability will occur if time-to-treatment failure is assessed in a study comparing the impact 
of psychiatric interventions and on time-to-treatment failure participants in one arm 
profitbenefit so substantially that they fail to return and are therefore lost from the study. 
5.2. Effect of censoring of participants with missing follow-up data on the hazard ratio
Factors that might result in a biased hazard ratio are the frequency of the outcome event of 
interest, the treatment effect in terms of the distribution of the outcome event between the 
study arms, and the frequency and distribution of censoring because of missing data (e.g. 
effect of intervention on the frequency of loss to follow-up). As the impact of dependent 
censoring on the hazard ratio cannot be determined based on the observed data (because the 
true outcome of censored individuals is not observable)), quantifications of the associated bias 
are difficult (15)(15). 
Nevertheless, the potential bias resulting from censoring of missing follow-up data can be 
substantial, especially when the outcome probability for those for whom data iswith missing 
data is considerably increased. In studies evaluating antiretroviral treatment programmes for 
HIV in settings with limited resources the, loss to follow-up rates are considerablytypically 
high. Performing a systematic review and meta-analysis of studies whereof such programmes 
in which individuals lost to follow-up in studies evaluating such programs were actively 
traced, for example by telephone calls or social networks, Brinkhof et al. (27) found that the 
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mortality among patients lost to follow-up in such studies was considerably increased as well. 
In a subsequent study Brinkhof et al. (28) found that the mortality among patients lost to 
follow-up was considerably increased. In a subsequent study, Brinkhof et al. (2829) then used 
the mortality estimates from their previous systematic review to impute representative 
mortality data for individuals lost to follow-up in an evaluation of five antiretroviral treatment 
programmes in sub-Saharan Africa. This study and found that survival analysis ignoring 
increased mortality among participants lost to follow-up greatly underestimated overall 
mortality and leads to a biased the evaluation of the programmeprogrammes.
In most situations, however, the reasons for censoring and the associated prognosis to 
experience the event of interest will notwill be availableunavailable to systematic review and 
guideline authors. Therefore, similar to assessments of a risk of bias in binary data analysis, 
one has to rely on the simplified principle, that the higher the frequency of dependent 
censoring of participants for whom (follow-up) data is missing in relation to the event rates 
and the greater the difference between the groups, the higher the potential for biased results 
(6). Simulations of single arm studies show that the degree of bias is more strongly influenced 
by the overall proportion of participants that are censored with an increased/decreased risk to 
experience the outcome, and thus dependently, rather than the differences in the hazard 
among study participants who are remaining at risk until the end of the observation period 
(29). In between-group comparisonsof experiencing the outcome, rather than the difference in 
the hazard of study participants who are remaining at risk until the end of the observation 
period and those who are censored (30). Between-group comparison simulations show that the 
degree of bias in settings with proportional hazards in Cox models is mainly enhanced by the 
overall degree and the early time- points of censoring for any reason (3031). 
5.3. Illustration of the uncertainty introduced through early dependent censoring to 
comparisons 
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In order to illustrate the impact of early depended censoring on survival analyses, we 
reconstructed individual participant data from the analysis of overall survival in a study by 
Denis et al. (32) (see also section 6.1). In this study example, the number of censored 
participants was different between the groups, particularly in the beginning of follow-up. 
Given the transparent reporting of outcome and censoring events in the available survival 
curve (Figure 2), we were able to reconstruct event and censoring time points for the 
individuals in each group (see Appendix A3). Box 1 provides a detailed description of the 
study example and Appendix A3 provides a summary of our proceeding to reconstruct 
survival data. We verified the consistency of our reconstructed dataset with the approach 
presented by Guyot et al. (33), that allows recreating individual participant level data from 
published survival curves by assuming constant censoring within a given time interval, and 
recalculated hazard ratios and Kaplan-Meier survival curves. 
To demonstrate the impact of early censoring on results, we considered a hypothetical 
scenario in which all participants who were censored prior to seven months of follow-up 
experience the event one month after censoring, i.e. these data are no longer censored but are 
counted as events. This assumption represents the extreme case of a very large positive 
correlation between early censoring and the experience of the event of interest. 
Appendix A4 figures 1 and 2 show the Kaplan-Meier survival curves for the reconstructed 
dataset and the hypothetical scenario. The original hazard ratio resulting from the authors’ 
analysis is 0.32 (95% confidence interval (CI) 0.15 to 0.67). The hazard ratio resulting for the 
data we reconstructed from the published survival curve was 0.32 (95% CI 0.15 to 0.65) 
showing that our reconstructed data set is nearly identical to the original one. The original 
analysis indicates a substantial survival advantage for participants in the experimental arm 
under the questionable assumption of independent censoring. 
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Appendix A4 figures 1 and 2 illustrate that a positive correlation between early censoring and 
the experience of the event of interest leads to an overestimation of the survival probability in 
both study arms. As more participants in the intervention arm are censored prior to seven 
months compared to the control arm (26 participants versus 19 participants), the hazard ratio 
increases to 0.69 (95% CI 0.44 to 1.07) in the hypothetical scenario. This illustrates that the 
effect estimation is biased if there is a positive correlation between early censoring and the 
experience of the event of interest and additionally a higher proportion of censored 
participants in the intervention arm. Therefore, there is a loss of certainty in the results of 
survival analyses in the case of substantial censoring, particularly throughout the early periods 
of follow-up and where no information is available on the reasons for censoring.
6. Suggestions to assess risk of bias resulting from censoring in an individual study
6.1. Identifying risk of bias due to censoring in individual studies
To appropriately assess the potential bias for study results emerging from dependent 
censoring of participants for whom follow-up data is missing, reasons why individual 
participants were censored for each outcome would be informative. Wherehelpful. When 
information onregarding the number of censored individuals with reasons together with the 
time- point of censoring isare available, imputation procedures based on assumptions, similar 
to those described in the GRADE guidance paper for missing outcome data within binary data 
analysis, could be applied to assess the robustness of effect measures to loss to follow-up 
(7)(7). 
Unfortunately, it is unlikely that review authors will be able to obtain data on the reasons and 
time-points for censoring for study participants and the reporting of information on missing 
data such as the mechanisms of missingness in RCTs is shown to be flawed (31). Before 
assessing a potential bias, it is recommended to gather all available information on possible 
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mechanisms for censoring, occasionally from the primary study investigators themselves. 
points for censoring for study participants and the reporting of information on missing data 
(34). Nevertheless, before assessing a potential bias, gathering all available information on 
possible mechanisms for censoring, if possible from the primary study investigators 
themselves, is likely to be helpful. 
For an informed judgement of risk of bias resulting from censoring of participants because of 
missing follow-up data, both the degree and the distribution of censoring among the study 
groups over time should be available. In randomized trials with a valid randomization process, 
censoring events resulting from treatment independent covariates (independent censoring) 
should have a similar distribution over time in both treatment arms. WhereAn unequivocal 
difference in the distribution of individuals lost to follow-up over-time unquestionably differs 
between the arms, for example a high number of early censoring in one arm versus late 
censoring in the other arm, this may, is likely to indicate the dependence of these censoring 
events. 
Differences in early censoring are especially relevant here because they can, in most 
situations, be more easily associated with missing follow-up data than “end-of study 
censoring”. In the absence of individual patient data, investigators maywill need to rely on 
information about the study participants throughout the course of the study that is available 
from reports. Most informative are survival curves and the number of reported individuals at 
risk to experience the outcome event across the study period. 
It is good practice, even though not consistently done, to indicate in the survival curves the 
time points whereat which individuals were censored in the survival curves (16, 22). This is 
often done by study authors by marking censoring time- points on the survival curves, e.g. as 
vertical lines, or as number of participants censored between given time points displayed 
along the number of participants at risk for these time points. This information then allows an 
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assessment of whether censoring happened early or late throughout the observation period and 
to assess differences in this distribution between study arms. For
Figure 2 presents an example please see figure 2 wherein which considerably more 
participants are censored in the intervention arm during the first months of the study as 
indicated by the vertical lines crossing the survival curves of the treatment arms. Box 1 
presents a detailed description of the example. (see also section 5.3). 
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Figure 2: Kaplan-Meier curve for the outcome overall survival from the study Denis et al 
(32). The vertical lines crossing the curves mark censored events. The elliptical form indicates 
that the number of early censored individuals is higher in the experimental arm compared to 
the control arm. The rectangular form shows that the number of participants at risk to 
experience the event for certain time points is reported below the curves for each study arm 
and are similar for both groups at 5 and 10 months of follow-up, despite a more favourable 
survival probability in the experimental arm. (32). Adapted from “Randomized Trial 
Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients” 
by Denis et al., 2017, Journal of the National Cancer Institute, 109(9), p. 6. Copyright 2017 
by Oxford University Press. Adapted with permission.
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Box 1: example 1: Denis et al. (32): 
In a randomized trial comparing a web mediated follow-up strategy with routine surveillance for participants 
suffering from lung cancer, the primary end point was overall survival (OS) defined from random assignment 
to death or to the last assessment of patient’s status when the patient was censored. A hazard ratio between 
groups was calculated using a Cox proportional hazards model. A total of 133 participants were randomized, 
and after exclusions of participants found after randomization to be ineligible, 60 and 61 participants were 
included in the modified intention-to-treat analyses in the intervention and the control arms respectively. The 
number of reported deaths per arm was 11 versus 26 and the number of relapses 34 versus 36. The study was 
closed early at an interim analysis by recommendation of the independent data monitoring board.
The degree of censoring was not reported throughout the study publication. However, an assessment of the 
presented survival curve (figure 2) shows substantially more censoring of participants in the experimental 
arm, particularly during early follow-up. Despite the visible survival benefits and the statistically significant 
hazard ratio in favour of the intervention group, the number of patients at risk is similar for both treatment 
arms at months 5 and 10. This suggests that a similar number of individuals who died in the control arm must 
have been censored in the intervention arm. This severe imbalance, despite randomization of the participants, 
introduces high risk to bias due to censoring of participants with missing follow-up data. In a hypothetical 
scenario, where individuals lost to follow-up are more likely than those who were not lost to follow up to die 
shortly after censoring, the survival benefit shown by the hazard ratio in the study is likely inflated and 
possibly inexistent. Here we would suspect a high risk of bias and, in a situation where only one study is 
included in the body of evidence or other included studies have similar imbalances , we would consider 
rating down due to study limitations for overall survival.
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If only a survival curve and the number at risk for particular time- points are available and 
direct information on the distribution of censoring is not presented (e.g. no censoring marks 
on the curves) or assessable (e.g. single marks for censoring not distinguishable on the curve 
due to high degree of censoring), it is sometimes possible to estimate the degree of 
participants censored for a certain time point from the given information by comparing the 
visible survival benefits in the curves and the number at risk for the reported time points 
(20).(20). In figure 2, for example, at five and ten months of follow-up, the same or a similar 
number of participants at risk are reported in both treatment arms (5 months: 37 versus 36; 10 
months: 19 versus 19). Comparing this information with the visible differences in survival 
probabilities in the curves, noticeably favoring the experimental arm, allows the conclusion 
that substantially more participants have been lost to follow-up in the experimental than in the 
control arm. This is because after five and ten months of follow-up, approximately the same 
number of individuals that experienced the event (death) in the control arm must have been 
lost to follow-up in the experimental arm. ForBox 1 presents a detailed description of the 
example see box 1. 
In situations whereWhen authors report the number of individuals for several time- points is 
reported together with the survival curves, established methods to reconstruct summary time-
to-event data also allow to approximateapproximations of the number of individuals censored 
within certain time intervals (11, 3335). Where. When authors provide the number of 
individuals at risk is given for a sufficient number of time points in the primary study report, 
such procedures may also be conclusively used and can support an assessment of the 
distribution of censoring in the study arms over time. Considerable variation in the overall 
difference and a difference in the distribution in terms of early versus late censoring between 
arms can then confirm a high risk of bias and a critical limitation to the effect estimator of a 
time-to-event outcome of an individual study. We encourage review and allowing guideline 
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authors to carefully and transparently justify their decisions. AnBox 2 and figure 3 provide an 




Figure 3: Kaplan-Meier curve for the outcome invasive disease-free survival from the study 
Martin et al (3436) (see Box 2). The number of individuals censored up to the respective time-
points of follow-up are reported along the number of individuals at risk to experience the 
outcome at this time point. The number of censored individuals is substantially higher in the 
neratinib arm throughout the follow-up period. The number of individuals at risk (excluding 
those who experienced the event or were censored) in the placebo arm is substantially higher 
than the number of individuals at risk in the neratinib arm. Nonetheless, the neratinib arm is 
shown to be beneficial by the HR (<1). Adapted from “Neratinib after trastuzumab-based 
adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a 
randomised, double-blind, placebo-controlled, phase 3 trial” by Martin et al., 2017, The 
Lancet Oncology, 18(12), p. 1694. Copyright 2017 by Elsevier. Reprinted with permission.
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Box 2: Example 2: Martin et al. (3436) 
The randomised, double blind, placebo-controlled ExteNET study compared adjuvant neratinib and placebo 
in patients with HER2-positive breast cancer after standard locoregional treatment, trastuzumab, and 
chemotherapy. The five-year analysis of the primary endpoint invasive disease-free survival which was 
defined as time from randomisation to first occurrence of invasive disease and recurrences or all cause death 
showed a significant benefit for the intervention. Hazard ratios were derived from a Cox proportional hazards 
model and individuals were censored for the primary end-point when they did not re-consent for additional 
follow-up at the date of their last physical examination, if disease recurrence did not occur within the 2 years 
of follow-up in this study or if they did not have a disease-free survival event within the relevant time-frame 
(5.6 months). In each treatment arm 1420 participants were randomized and included in the intention-to-treat 
analysis.
While the study publication did not specify the proportion of censored individuals and the respective reasons 
for censoring, the survival curve for the primary outcome (figure 3) shows severe imbalances in the number 
of censored individuals. The number of censored participants between the time-points is reported together 
with the number of participants at risk to experience the event for certain time points below the curves and 
for each study arm respectively. The percentages present the proportion of participants who are event-free for 
the respective time-points. The number of censored individuals in the experimental arm is substantially 
higher than in the placebo arm, especially in the early observational period. This results in a lower number of 
individuals is at risk, excluding those who have experienced the event of interest or were censored, at any 
time point thereafter in the favored experimental arm. Assessing the times for the beginning of accrual (July 
9, 2009), the ending of accrual (October 24, 2011) and the end of the five year follow-up (March 1, 2017) 
one can be certain that the early censoring events were due to loss to follow-up, and not to “end-of-follow-
up”, because the minimum complete observation time was at least 5.4 years (from Oct 24, 2011 - March 1, 
2017). Given the information outlined above, a judgement of high risk of bias for this study due to censoring 
of participants because of missing follow-up data is justifiable. In a hypothetical situation, where a body of 
evidence for a certain outcome consists solely of this example, we would consider rating down for study 
limitations.
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6.2 What to do when individual studies do not provide the distribution of censoring over time 
is not known in individual studies
Review authors often find themselves in situations where thein which they must assess 
potential risk of bias through censoring of participants because of missing follow-up data 
must be made based on only very limited information (16-19). When the distribution of 
censoring over time in individual studies is not clear, but there are serious imbalances in the 
number of individuals for whom data is missing (e.g. individuals lost to follow-up 
summarized in a study flow-diagram) in the study arms or the reasons for the absence of 
follow-up data differ among arms (e.g. provided in a study flow-diagram), we suggest, in 
accordance with the Risk of Bias 2.0 tool, concern for a high risk of bias (“probably yes”) for 
an individual study outcome. (23, 24). To derive a decision, the instructions for risk of bias 
due to loss to follow-up in binary data analysis from the GRADE guideline on study 
limitations (risk of bias) should be considered (6). For time-to-event analyses from individual 
studies that do not report information regarding the distribution of censoring over time, its 
degree, and reasons, we suggest to explicitly statestating that a judgement was not possible 
because the required information was absent.
6.3. Individual participant data would be desirable to assess the risk of bias
Within-study sensitivity analyses for censoring, such as best/worst-case scenarios and other 
imputation procedures, require individual participant data. If data on individual failure and 
censoring times and reasons are available, individual patient data meta-analyses for time-to-
event outcomes would allow for a more elaborate assessment of the sensitivity of results to 
missing data issues. So, for
For example, such analyses may be possible when data for individuals lost to follow-up can 
be imputed based on plausible assumptions for individuals for whom data is missing (7)(7). 
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Significant changes in the estimates could then lead to decisions to rate down the certainty of 
evidence. Available statistical tests for the independence assumption also require additional 
data (35). However, they(37) and are usually impossible to perform, when conducting a 
standard systematic review. Simple quantification measures for the completeness of follow-up 
in survival analyses also exist, but are usually not included in study reports. 
6.4. Rating the risk of bias resulting from censoring of participants because of missing follow-
up data and deriving an overall judgement for an individual study
Indicators Considerations for the risk of bias through censoring of 
participants with missing follow-up data assessment in 
individual studies
Time point of censoring considerably 
different in both arms (early versus late 
censoring)
Critical concern for high risk of bias as early censoring is more 
likely to be due to missing data (e.g. loss to follow-up) as 
opposed to end of study censoring.
Censoring degree among arms diverging 
(Overall number of censored patients 
reported, but distribution over time not 
known)
If reasons for censoring are reported (e.g. 
summarised in a study flow diagram): 
Different reasons why data for individuals 
was missing (e.g. were lost to follow-up) 
and different degree between arms.
A high risk of bias is more likely as a different degree and 
differing reasons for censoring are contradicting with a valid 
randomization process and thus imply that missingness may 
depend on the received intervention (23)
A high risk of bias is more likely as a different degree and 
differing reasons for censoring are contradicting with a valid 
randomization process and thus imply that missingness may 
depend on the received intervention (23)
Table 1: Decision support for judgements of a risk of bias though inappropriate censoring in an 
individual study
A judgment on the risk of bias associated with missing data for time-to-event outcomes within 
GRADE should be based on the principles outlined in previous guidelines for rating the 
quality of the evidence addressing study limitations (GRADE guideline 4), particularly with 
regard to the risk of bias associated with missing participant outcome data in a body of 
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evidence for both binary and continuous outcomes (GRADE guideline 17) (6, 7). The 
assessment criteria specified in this guidance allow to integrateintegration of time-to-event 
specific differences (e.g. censoring of individuals for whom data is missing and those who 
ended follow-up appropriately) and to support a decision on the presence of a risk of bias. 
Table 1 provides considerations that reviewers can be useduse to estimate the extent of the 
risk of bias introduced by censoring of participants because of missing data in an individual 
study. To derive a decision on the impact of missing follow-up data on the overall risk of bias 
for an outcome in an individual study reviewers must consider all other potential study 
limitations, for example the including lack of allocation concealment, or the lack of blinding 
and selective outcome reporting, within a body of evidence for a particular time-to-event 
outcome must be considered. A rating can then be made following thewhich they can judge 
risk of bias can following usual GRADE principles of the GRADE approach (6). Accordingly, 
aA crucial limitation in one risk of bias criterion, which may include substantial differences in 
the degree and distribution in the amount of early and late censoring, or several criteria with 
some limitations, which may include considerable difference in the overall degree of 
censoring, that aremay be sufficient to lower ones confidence in an effect would allowmerit a 
judgement of a serious limitation. In case there is aA crucial limitation for one or more criteria 
which are sufficient to substantially lower the confidence in an effect estimate, this would 
result in a judgement of a very serious limitation for the outcome of an individual study (6). 
These judgements should then inform an overall rating of the GRADE risk of bias domain for 
a body of evidence. 
7. Making an overall judgement for a body of evidence
To derive a judgment for the risk of bias domain across studies in a body of evidence, 
reviewers should apply the usual GRADE principles for study imitations have to be applied 
(6): no serious limitations (do not rate down), if the outweighing information is contributed 
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byevidence comes largely from studies ofat low risk of bias; serious limitations (rate down 
one level), if the outweighing information is contributed byevidence comes largely from 
studies at moderatehigh risk of bias; very serious limitations (rate down two levels), if the 
outweighing information contributed byevidence comes largely from studies at very high risk 
of bias. Depending on the individual situations one may also consider to exclude
If studies with very serious limitations from the bodyvary in their risk of bias, and results 
differ in high and low risk of evidence bias studies, reviewers may base best evidence 
summaries on the lower risk of bias studies (6).
 In particular, in an appropriately large set of studies, when the potential risk of bias due to 
censoring of participants with missing lost to follow-up data differs across studies, sensitivity 
analyses excluding studies with a high risk of bias or studies where there are some concerns 
should be performed. Review and guideline authors are encouraged to integrate these results 
into their overall judgements. In case of substantial changes, including a change of direction 
of the pooled effect estimate, systematic review or guideline authors should consider rating 
down the certainty of the evidence for study imitations (risk of bias).reviewers can conduct 
sensitivity analysis to determine whether results differ in high and low risk of bias studies. 
When results differ, reviewers should present best estimates from only low risk of bias 
studies.
8. Discussion and further guidance for the assessment of time-to-event evidence
For this guide we chose the prior outlined definitions and concepts, but they are not 
unassailable. Well-known resources for the conduct of systematic reviews focus on the hazard 
ratio as relative effect measure to include time-to-event data in meta-analyses (36). Therefore, 
our guidance focuses on the hazard ratio as(38). Therefore, our guidance focuses on the 
hazard ratio as the relative effect measure for time-to-event analysis. In time-to-event analysis 
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certain competing risk analyses require censoring of competing events, meaning single or 
multiple events precluding the occurrence of the event of interest, by default (13, 37). 
Nevertheless, such analyses are likewise susceptible to bias due to censoring of participants 
because of missing follow-up data, when individuals are excluded from follow-up and 
censored for other reasons. An exception is (13, 39). 
Nevertheless, such analyses remain susceptible to bias due to censoring of participants 
because of missing follow-up data when individuals are excluded from follow-up and 
censored for other reasons. An exception occurs when study authors applied competing risk 
analysis methods to account for the particular reasons data is absent, e.g. loss to follow-up, in 
their primary analysis. 
To illustrate the issues outlined in this guidance we present examples from randomized trials; 
some considerations are, however, also applicable also to non-randomized studies with 
control arms. In the absence of randomization, confounders may introduce bias because of an 
association between censoring time and the outcome of interest and the control of such 
confounders plays a critical role (3840). We acknowledge the changeabilitypossible 
subsequent progress of the field and will adapt this guidance as necessary.
There is aA great variety of additional approaches to analyze time-to-event data, which are 
applied apply less frequently for primary analyses and rarely find their way into meta-
analyses. NumerousInvestigators have proposed numerous analytic techniques to test the 
sensitivity of single trial results to the dependence of censoring have been proposed. Several, 
several of the methodswhich are based on multiple imputation and account for the dependence 
of follow-up, taking the distribution of survival events into account. 
These approaches are not solely aiming atapplicable to the Cox model, but address Kaplan-
Meier estimators, parametric proportional hazards models and other analysis techniques. 
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Practical applications of the methods show substantial bias when the survival expectation of 
the censored individuals alters in a negative or positive manner from the expectation of the 
individuals remaining on study (39-4741-49). Computationally more advanced methods, 
including approaches that explicitly allow for adjustment of dependent censoring are based on 
strict assumptions, require a detailed data, and are currently used only for exploratory 
purposes only. In situations where. When the results of such procedures are available they can 
support a judgement on the consequences of censoring, if properly applied (48-50-52). 
Censoring is an important threat to the validity of safety analyses, becauseBecause the 
occurrence of adverse events is usually carried out as binary data analysis in contingency 
tables., censoring is an important threat to the validity of safety analyses. However, when 
comparing adverse events among different studiesstudy arms, all individuals should be 
observed for a similar time-period to allow a fair comparison of interventions. Censoring of 
participants from individual study arms, for example because of competing events such as 
censoring atswitching treatment switching after disease progression, results in varying 
observation times among participants and subsequently in diverging average times at risk for 
adverse events in comparisons between study arms. Bender et al. (51) pointed out specific 
situations where. Bender et al. (53) pointed out specific situations in which the risk of bias 
due to inadequate analysis of adverse events led to significant reductions of the certainty in 
the evidence in evaluations to inform reimbursement decisions for new drugs by the relevant 
authorities in Germany as “greater harm could not be excluded with sufficient certainty”. 
Analysis of safety endpoints by means of appropriate time-to-event analysis techniques is 
required and should be common practice (52).(54).
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Appendix A.1A1: Independent and non-informative censoring
Non-informative censoring, as described by Lagakos (15)Lagakos (15), requires “that the 
time-point of a censoring event holds no information about an individual’s likelihood to 
experience the event of interest (its survival time)”. This means that the true distribution of the 
survival time, where no individual is lost from observation and individuals are observed until 
the event occurs, and the true censoring distribution, where the study ends before all subjects 
experience the event and censored individuals do not experience the event prior to the end of 
study, provide no information for each other. Informative censoring is sometimes referred to 
as a type of selection bias under the reasoning that loss to follow-up or withdrawal in 
randomized trials leads to selection after randomization, when certain participants due to 
certain measured or unmeasured characteristics or conditions may be less likely or more likely 
to be censored and as well less likely or more likely to experience the event of interest. In 
other words, the association of the risk of being censored and the risk of experiencing the 
event results from a common source of both risks (3840). The definition of independent 
censoring is not equivalent to non-informative censoring and Lagakos (15)Lagakos (15) 
shows that dependent censoring is a special form of informative censoring, however, in most 
situations where the assumption of independent censoring is violated, the assumption of non-
informative censoring is too (13)(13). 
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Appendix A.2A2: Reporting requirements for survival analysis that allow to assess the risk of 
bias due to censoring
In order to assess the suitability of the independent censoring assumption by users, including 
systematic review and guideline authors, the methods in a primary study report should ideally 
provide detailed definitions of the assessed outcomes including the event(s) of interest, the 
time of origin and all conditions leading to censoring despite end-of observation (e.g. absence 
of the event at study closure, loss to follow-up or withdrawal due to competing events) (17, 
18). Standardized outcome definitions would here be highly preferable (19)(19). With regard 
to the applied analysis methods we would demand that it is explicitly reported why the 
assumption of dependent censoring is feasible. When outcomes which include competing 
risks are assessed, we would require the application and reporting of appropriate methods, 
which will be outlined in a future guidance. The result section should hold the total events of 
interest and number of censored individuals in each of the study arms and the number of 
participants censored separately of those before the end the observational period including the 
individual reasons (17, 18). It is highly desirable that Kaplan-Meier curves, if feasible, are 
given for each of the assessed outcomes. In the curves, the time-points of censored events 
should be indicated as well as the number at risk below the curves for appropriate time-points 
(22)(22). The number of censored individuals for certain time-points with an indication of 
censoring reasons is an option to enhance transparency. Lastly, the duration of follow-up for 
each study arm should be given and the calculation method should be clearly stated (5355).
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Appendix A3. Reconstruction of survival data to illustrate the impact of early dependent 
censoring
To illustrate the impact of early dependent censoring on comparisons, we reconstructed 
individual participant data from the survival curves published for the analysis of overall 
survival in the article by Denis et al. (32). The study shows an unbalanced number of 
censored participants particularly during early follow-up, with more censored participants in 
the intervention arm compared to the control arm. Given the clear reporting in the survival 
curves, we were able to reconstruct outcome event and censoring time points for the 
individuals in each of the compared groups. We verified our proceeding with the algorithm 
presented Guyot et al. (33) that allows to reconstruct individual participant level data from 
published survival curves. The algorithm attributes a constant rate of censoring to intervals in 
between outcome events and time-points for which a number of individuals at risk is reported. 
It therefore works optimal assuming independent censoring. Under the objective of our 
illustration, we decided not to directly use the dataset resulting from the algorithm proposed 
by Guyot and colleagues but to work with individual patient data that we reconstructed 
directly from the published survival curve. Nevertheless, we used the data set produced under 
application of the algorithm to confirm the consistency of our manually extracted data by 
comparing the data points retrieved through both approaches. 
We extracted data with the software DigitizeIt (www.digitizeit.de), which allows to assign 
each point on the survival curve a corresponding time-point on the x-axis. We marked all 
declines of the curve as outcome event and all crosses as censoring time-points. The reported 
curve for the experimental arm was unclear for two censoring events in the first interval (0 to 
5 months) and the last interval (over 15 months) respectively, which were not directly 
identifiable on the curve, but must have occurred in these intervals as indicated by the number 
of individuals at risk. Similarly, for the curve representing survival in the control arm, two 
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censoring events were not identifiable within the first interval (0 to 5 months). For all 
scenarios we assumed the missing censoring events to have happened on the last possible 
time-point of this interval (4.99 and 18.99 months). In the so retrieved dataset, we modified 
the survival data of participants censored within the first seven months of follow-up to 
illustrate the impact of early dependent censoring. We present a hypothetical scenario where 
all participants censored prior to seven months of follow-up experience the outcome event one 
month after the original censoring. Subsequently, we calculated hazard ratios with the Cox 
proportional hazards model and present Kaplan-Meier survival curves. All statistical analyses 
were performed using the software R (56). We want to point out that our imputation does not 
claim to compare a difference in treatment effects, but to illustrate the loss of certainty that is 
introduced to survival analyses through a high degree of censoring particularly during the 
early period of follow-up.
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Appendix A4. Reconstructed survival curves
Appendix-figure 1: Kaplan-Meier survival curves calculated from the individual participant level 
data reconstructed from the analysis of overall survival in Denis et al. (32). 
Appendix-figure 2: Kaplan-Meier survival curve calculated from the individual participant level 
data reconstructed from the analysis of overall survival in Denis et al. (32). Participants who 
were censored prior to seven months of follow-up in both study arms were set to experience the 
outcome event one month after original censoring.
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GRADE Guideline:
Rating the certainty in time-to-event outcomes – Study limitations due to censoring of 




 Analysis methods for time-to-event outcomes deal with participants for whom 
outcome data is unavailable through censoring. Two types of censoring, end of study 
censoring and censoring because of missing data (commonly named loss to follow-up 
censoring), have to be differentiated.
 Censoring of individuals with missing follow-up data is likely to violate the 
assumption of independence of censoring and increases the risk of biased results.
 The magnitude of bias resulting from censoring of participants with missing data 
depends on several factors. An increasing degree of dependent censored observations 
and difference among the study arms, increases the risk of bias.
What are the implications and what should be changed?
 Often, reasons why individuals in studies were censored and the time-points of 
censoring are unavailable to systematic review and guideline authors who therefore 
have to make risk of bias judgements for primary studies based on the distribution of 
censoring over time or the degree of missing participant follow-up data.
 Systematic review and guideline authors need to make GRADE judgements across the 
body of evidence for study limitations resulting from censoring of participants with 
missing data considering all available information, including the possibility of 
carrying out sensitivity analysis by assessing whether studies at high risk of bias or 
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Objective: To provide Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE) guidance for the consideration of study limitations (risk of bias) due to 
missing participant outcome data for time-to-event outcomes in intervention studies.
Study Design and Setting: We developed this guidance through an iterative process that 
included membership consultation, feedback, presentation and iterative discussion at meetings 
of the GRADE Working Group.
Results: The GRADE working group has published guidance on how to account for missing 
participant outcome data in binary and continuous outcomes. When analysing time-to-event 
outcomes (e.g. overall survival, time-to-treatment failure) data of participants for whom the 
outcome of interest (e.g. death, relapse) has not been observed are dealt with through 
censoring. To do so, standard methods require that censored individuals are representative for 
those remaining in the study. Two types of censoring can be distinguished, end of study 
censoring and censoring because of missing data, commonly named loss to follow-up 
censoring. However, both types are not distinguishable with the usual information on 
censoring available to review authors. Dealing with individuals for whom data is missing 
during follow-up in the same way as individuals for whom full follow-up is available at the 
end of the study increases the risk of bias. Considerable differences in the treatment arms in 
the distribution of censoring over time (early versus late censoring), the overall degree of 
missing follow-up data and the reasons why individuals were lost to follow-up may reduce the 
certainty in study results. With often only very limited data available, review and guideline 
authors are required to make transparent and well-considered judgements when judging risk 






























































Conclusion: Concern for risk of bias resulting from censoring of participants for whom 
follow-up data is missing in the underlying studies of a body of evidence can be expressed in 
the study limitations (risk of bias) domain of the GRADE approach.
Keywords
GRADE; Certainty of the evidence; Time-to-event outcomes; Survival analysis; Risk of bias; 































































 Analysis methods for time-to-event outcomes deal with participants for whom 
outcome data is unavailable through censoring. Two types of censoring, end of study 
censoring and censoring because of missing data (commonly named loss to follow-up 
censoring), have to be differentiated.
 Censoring of individuals with missing follow-up data is likely to violate the 
assumption of independence of censoring and increases the risk of biased results.
 The magnitude of bias resulting from censoring of participants with missing data 
depends on several factors. An increasing degree of dependent censored observations 
and difference among the study arms, increases the risk of bias.
What are the implications and what should be changed?
 Often, reasons why individuals in studies were censored and the time-points of 
censoring are unavailable to systematic review and guideline authors who therefore 
have to make risk of bias judgements for primary studies based on the distribution of 
censoring over time or the degree of missing participant follow-up data.
 Systematic review and guideline authors need to make GRADE judgements across the 
body of evidence for study limitations resulting from censoring of participants with 
missing data considering all available information, including the possibility of 
carrying out sensitivity analysis by assessing whether studies at high risk of bias or 






























































The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
working group has defined domains that can limit the certainty in a body of evidence (1-6). 
Within its study limitations domain (i.e., risk of bias), the GRADE approach has issued 
guidance on how to account for missing participant outcome data for binary and continuous 
outcomes (6, 7). That guidance proposes conducting sensitivity meta-analyses making 
assumptions about the outcomes of participants with missing data, to test the robustness of the 
findings of the primary meta-analysis (7, 8). 
Although the basic principles for assessing risk of bias associated with missing participant 
outcome data in binary outcome analysis also apply to time-to-event analysis, there are issues 
uniquely applicable to time-to-event outcomes. In contrast to binary data analysis, time-to-
event studies, which assess not only whether an event of interest occurs but also when it 
occurs, typically follow patients for varying periods of time. Because time-to-event analyses 
include data from individuals with variable lengths of follow-up, those for whom follow-up 
data becomes absent during the study interval are typically treated in the same way as those 
with regular follow-up until the end of the analysis (i.e. they provided complete data). 
Therefore, we here refer to missing follow-up data to characterize the situation when 
information for an individual becomes absent at a time-point within the intended and pre-
specified observation period. This article discusses GRADE rating of study limitations 
associated with missing follow-up data when dealing with time-to-event analysis.
2. Background
2.1. Time-to-event analysis and censoring
Time-to-event analysis is also often referred to as survival analysis, in which the “survival 





























































analyse time-to-event outcomes include Kaplan-Meier curves along with the log-rank test and 
the Cox proportional hazards regression model (9, 10). Time-to-event outcomes are often 
described by survival rates, defined as the probability that an individual will not have 
experienced an event (e.g. “survived”) up to a certain time point, or hazard rates, which can 
be interpreted as instantaneous failure rates, meaning an individual’s likelihood of 
experiencing an event (e.g. “death”) at a certain time point given that the event has not 
occurred up to this time point. 
The most prominently applied relative effect measure is the hazard ratio, which is the ratio of 
hazards between two groups. It is commonly obtained from the Cox proportional hazards 
regression model, which adjusts for relevant covariates and confounders. An unadjusted 
hazard ratio can also be derived indirectly using other analytical techniques, like the Kaplan-
Meier method or the log-rank test (10, 11). 
A core feature of time-to-event analysis is the consideration of “censoring” which occurs 
when patients complete their follow-up period without having experienced the event of 
interest. Censored observations are included in analyses to optimize the efficiency that time-
to-event analysis provides over binary data analysis (12). If the time to an event and censoring 
are not included in the calculation of the (log) hazard ratio, it equals the (log) relative risk. 
To include censored observations in time-to-event analyses, general methods of survival 
analysis require an assumption of non-informative and independent censoring. Violations of 
this assumption introduce risk of bias. Appendix A1 provides a short review of the definition 
of non-informative censoring and its relation to independent censoring. In accordance with 
established training resources for time-to-event analysts (13), we will use the concept of 
independent and dependent censoring to describe situations under which censoring may lead 





























































Independent censoring occurs when censored participants and those remaining under 
observation have the same probability of experiencing the event of interest, as if the censored 
individuals were “randomly drawn” during the course of follow-up (13, 14). An example for 
censoring mechanisms independent from the survival time (and also non-informative) is 
administrational closure of a study. Differences in the observation times of participants then 
are solely a result of the staggered study entry times and the fixed study closure time (figure 
1) (13, 15).
Figure 1: Types of censoring: For participant 1 the occurrence of the outcome event is 
observable. Participants 2 and 3 are censored because of the administrational closure of the 
study. The variation in their duration of follow-up and the differing censoring time points result 
from the staggered recruiting phase of the study. Participant 4 is lost from the observation 
before the administrational ending of the study and censored for a different reason. 
When individuals are censored because of missing follow-up data, this assumption is likely to 
be violated. Examples of such situations which may bias results include:
 Participants withdraw consent due to physical or mental side effects of an 
intervention;
 Participants are withdrawn from the observation and censored following switching 
treatment as a result of progressive disease;
 Investigators fail to locate study participants.
2.2. Reporting time-to-event data and censoring in primary studies
Flaws in reporting time-to-event analyses may complicate their adequate appraisal by 
systematic review authors including assessing risk of bias resulting from censoring of 
individuals with missing follow-up data (16-19). Suboptimal reporting includes but is not 





























































as the number of participants at risk at certain time points, and details of statistical model 
building. Authors often fail to precisely define censoring mechanisms, omit the number of 
censored participants, and fail to state why individual study participants were censored (16-
19). 
Studies published in leading medical journals are not immune to reporting limitations: for 
instance, one methodological study found inconsistency between the number of participants 
reported in the text/tables as ‘lost before the end of the study’ and those assessed from 
Kaplan-Meier curves (20). Prior work has specified minimal reporting items for time-to-event 
analyses and survival curves (17, 18, 21, 22). Appendix A2 outlines reporting requirements 
that allow systematic review and guideline authors to assess possible risk of bias resulting 
from informative censoring. 
3. Methods
This guidance was developed by members of the GRADE working group. They included 
methodologists, clinical epidemiologists and biostatisticians with experience in systematic 
reviews and/or guideline development. The group developed the guidance based on iterative 
discussions by email, on conference calls and at a GRADE working group meeting in 
Manchester, UK, in October 2018. The final draft of the guidance was presented during the 
GRADE working group meeting in Hamilton in June 2019 and was approved following the 
group’s standard approval process.
4. Scope
This guidance aims to support systematic review and guideline authors in the assessment of 
study limitations (risk of bias) due to missing follow-up data for time-to-event outcomes in 
intervention studies. We describe an approach that takes a systematic reviewer perspective 





























































accompanying records. To comply with well-known resources for systematic review authors 
to assess the risk of bias in individual studies and with reference to previous GRADE 
guidance for rating the certainty of the evidence with focus on study limitations (risk of bias), 
we refer to missing follow-up data as the unavailability of follow-up data for individuals 
during the study interval (6, 23, 24). This includes all types of missing data and situations in 
which the outcome status of study participants becomes unavailable during the study period 
irrespective of the reason (e.g., patients not available or inappropriately excluded) (25, 26). 
The concerning risk of bias arises, for example, when investigators censor individuals for 
whom data is missing and include them in the computation of effect measures in the same 
way as participants with independent censoring (e.g., those whose follow-up ended 
appropriately at the end of the data collection period). Systematic review and guideline 
authors seldom have information regarding the reasons for censoring for each participant in 
every eligible study. Consistent with well-known instructions for systematic review authors, 
we therefore provide guidance that is primarily aimed at detecting a potential bias in 
individual studies (23, 24). Judgements on study level then inform the risk of bias assessment 
for an overall body of evidence separately for each outcome.
In accordance with previous GRADE guideline for missing participant outcome data for 
binary and continuous outcomes, we provide guidance for systematic review and guideline 
authors who assess comparative clinical trials based on aggregated data (7). We differentiate 
the issue of adequately accounting for loss to follow-up from that of adherence to the 
intention to treat (ITT) principle, which relates to analyzing study participants with known 
data in the groups to which they were allocated (7, 27). 
We focus on risk of bias in the outputs of the “standard” methods of survival analysis and the 
Cox model hazard ratio as the single comparative relative effect size measure (16-19). Within 





























































the authors of meta-analyses have chosen the correct method for analysing competing events 
for the intended research question.
5. How censoring participants with missing follow-up data may affect the results of the 
study
5.1. Censoring of participants leading to over- and under estimation of the survival probability
Similar to binary outcome analysis, the distortion of the outcome probability of the group 
under study depends on the outcome probability of those for whom data is missing. When 
individuals who are more likely to experience the (negative) event of interest (e.g. death) are 
also more likely to be missing (positive correlation between the occurrence of the event and 
missingness of data), e.g. because they are more likely to be lost to follow-up, the true 
survival probability of a study group will inevitably be overestimated (12, 23). This means 
that the corresponding true risk of the (negative) event occurrence will be underestimated. 
Such an association may occur, for example, if participants with treatment-related adverse 
events are no longer followed-up and are censored at the time of loss to follow-up. 
On the other hand, in case of a negative correlation between the occurrence of the event and 
the probability of being censored, the true survival probability for a study group may be 
underestimated (and the corresponding true event risk overestimated) (23). For example, 
underestimation of the event-free survival probability will occur if in a study comparing the 
impact of psychiatric interventions on time-to-treatment failure participants in one arm benefit 
so substantially that they fail to return and are therefore lost from the study. 
5.2. Effect of censoring of participants with missing follow-up data on the hazard ratio
Factors that might result in a biased hazard ratio are the frequency of the outcome event of 
interest, the treatment effect in terms of the distribution of the outcome event between the 





























































effect of intervention on the frequency of loss to follow-up). As the impact of dependent 
censoring on the hazard ratio cannot be determined based on the observed data (because the 
true outcome of censored individuals is not observable), quantifications of the associated bias 
are difficult (15). 
Nevertheless, the potential bias resulting from censoring of missing follow-up data can be 
substantial, especially when the outcome probability for those with missing data is 
considerably increased. In studies evaluating antiretroviral treatment programmes for HIV in 
settings with limited resources, loss to follow-up rates are typically high. Performing a 
systematic review and meta-analysis of studies of such programmes in which individuals lost 
to follow-up were actively traced by telephone calls or social networks, Brinkhof et al. (28) 
found that the mortality among patients lost to follow-up was considerably increased. In a 
subsequent study, Brinkhof et al. (29) then used the mortality estimates from their previous 
systematic review to impute representative mortality data for individuals lost to follow-up in 
an evaluation of five antiretroviral treatment programmes in sub-Saharan Africa and found 
that survival analysis ignoring increased mortality among participants lost to follow-up 
greatly underestimated overall mortality and leads to a biased evaluation of the programmes.
In most situations, however, the reasons for censoring and the associated prognosis will be 
unavailable to systematic review and guideline authors. Therefore, similar to assessments of a 
risk of bias in binary data analysis, one has to rely on the simplified principle that the higher 
the frequency of dependent censoring of participants in relation to the event rates and the 
greater the difference between the groups, the higher the potential for biased results (6). 
Simulations of single arm studies show that the degree of bias is more strongly influenced by 
the overall proportion of participants that are censored with an increased/decreased risk of 
experiencing the outcome, rather than the difference in the hazard of study participants who 





























































Between-group comparison simulations show that the degree of bias in settings with 
proportional hazards in Cox models is mainly enhanced by the overall degree and the early 
time points of censoring for any reason (31). 
5.3. Illustration of the uncertainty introduced through early dependent censoring to 
comparisons 
In order to illustrate the impact of early depended censoring on survival analyses, we 
reconstructed individual participant data from the analysis of overall survival in a study by 
Denis et al. (32) (see also section 6.1). In this study example, the number of censored 
participants was different between the groups, particularly in the beginning of follow-up. 
Given the transparent reporting of outcome and censoring events in the available survival 
curve (Figure 2), we were able to reconstruct event and censoring time points for the 
individuals in each group (see Appendix A3). Box 1 provides a detailed description of the 
study example and Appendix A3 provides a summary of our proceeding to reconstruct 
survival data. We verified the consistency of our reconstructed dataset with the approach 
presented by Guyot et al. (33), that allows recreating individual participant level data from 
published survival curves by assuming constant censoring within a given time interval, and 
recalculated hazard ratios and Kaplan-Meier survival curves. 
To demonstrate the impact of early censoring on results, we considered a hypothetical 
scenario in which all participants who were censored prior to seven months of follow-up 
experience the event one month after censoring, i.e. these data are no longer censored but are 
counted as events. This assumption represents the extreme case of a very large positive 
correlation between early censoring and the experience of the event of interest. 
Appendix A4 figures 1 and 2 show the Kaplan-Meier survival curves for the reconstructed 





























































analysis is 0.32 (95% confidence interval (CI) 0.15 to 0.67). The hazard ratio resulting for the 
data we reconstructed from the published survival curve was 0.32 (95% CI 0.15 to 0.65) 
showing that our reconstructed data set is nearly identical to the original one. The original 
analysis indicates a substantial survival advantage for participants in the experimental arm 
under the questionable assumption of independent censoring. 
Appendix A4 figures 1 and 2 illustrate that a positive correlation between early censoring and 
the experience of the event of interest leads to an overestimation of the survival probability in 
both study arms. As more participants in the intervention arm are censored prior to seven 
months compared to the control arm (26 participants versus 19 participants), the hazard ratio 
increases to 0.69 (95% CI 0.44 to 1.07) in the hypothetical scenario. This illustrates that the 
effect estimation is biased if there is a positive correlation between early censoring and the 
experience of the event of interest and additionally a higher proportion of censored 
participants in the intervention arm. Therefore, there is a loss of certainty in the results of 
survival analyses in the case of substantial censoring, particularly throughout the early periods 
of follow-up and where no information is available on the reasons for censoring.
6. Suggestions to assess risk of bias resulting from censoring in an individual study
6.1. Identifying risk of bias due to censoring in individual studies
To appropriately assess the potential bias for study results emerging from dependent 
censoring of participants for whom follow-up data is missing, reasons why individual 
participants were censored for each outcome would be helpful. When information regarding 
the number of censored individuals with reasons together with the time point of censoring are 
available, imputation procedures based on assumptions, similar to those described in the 
GRADE guidance paper for missing outcome data within binary data analysis, could be 





























































Unfortunately, it is unlikely that review authors will be able to obtain data on the reasons and 
time points for censoring for study participants and the reporting of information on missing 
data (34). Nevertheless, before assessing a potential bias, gathering all available information 
on possible mechanisms for censoring, if possible from the primary study investigators 
themselves, is likely to be helpful. 
For an informed judgement of risk of bias resulting from censoring of participants because of 
missing follow-up data, both the degree and the distribution of censoring among the study 
groups over time should be available. In randomized trials with a valid randomization process, 
censoring events resulting from treatment independent covariates (independent censoring) 
should have a similar distribution over time in both treatment arms. An unequivocal 
difference in the distribution of individuals lost to follow-up over-time, for example a high 
number of early censoring in one arm versus late censoring in the other, is likely to indicate 
dependence of these censoring events. 
Differences in early censoring are especially relevant because they can be more easily 
associated with missing follow-up data than “end-of study censoring”. In the absence of 
individual patient data, investigators will need to rely on information about the study 
participants throughout the course of the study that is available from reports. Most 
informative are survival curves and the number of reported individuals at risk to experience 
the outcome event across the study period. 
It is good practice, even though not consistently done, to indicate in the survival curves the 
time points at which individuals were censored (16, 22). This is often done by study authors 
by marking censoring time points on the survival curves, e.g. as vertical lines, or as number of 
participants censored between given time points displayed along the number of participants at 





























































happened early or late throughout the observation period and to assess differences in this 
distribution between study arms. 
Figure 2 presents an example in which considerably more participants are censored in the 
intervention arm during the first months of the study as indicated by the vertical lines crossing 
the survival curves of the treatment arms. Box 1 presents a detailed description of the example 





























































Figure 2: Kaplan-Meier curve for the outcome overall survival from the study Denis et al 
(32). The vertical lines crossing the curves mark censored events. The elliptical form indicates 
that the number of early censored individuals is higher in the experimental arm compared to 
the control arm. The rectangular form shows that the number of participants at risk to 
experience the event for certain time points is reported below the curves for each study arm 
and are similar for both groups at 5 and 10 months of follow-up, despite a more favourable 
survival probability in the experimental arm. (32). Adapted from “Randomized Trial 
Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients” 
by Denis et al., 2017, Journal of the National Cancer Institute, 109(9), p. 6. Copyright 2017 





























































Box 1: example 1: Denis et al. (32): 
In a randomized trial comparing a web mediated follow-up strategy with routine surveillance for participants 
suffering from lung cancer, the primary end point was overall survival (OS) defined from random assignment 
to death or to the last assessment of patient’s status when the patient was censored. A hazard ratio between 
groups was calculated using a Cox proportional hazards model. A total of 133 participants were randomized, 
and after exclusions of participants found after randomization to be ineligible, 60 and 61 participants were 
included in the modified intention-to-treat analyses in the intervention and the control arms respectively. The 
number of reported deaths per arm was 11 versus 26 and the number of relapses 34 versus 36. The study was 
closed early at an interim analysis by recommendation of the independent data monitoring board.
The degree of censoring was not reported throughout the study publication. However, an assessment of the 
presented survival curve (figure 2) shows substantially more censoring of participants in the experimental 
arm, particularly during early follow-up. Despite the visible survival benefits and the statistically significant 
hazard ratio in favour of the intervention group, the number of patients at risk is similar for both treatment 
arms at months 5 and 10. This suggests that a similar number of individuals who died in the control arm must 
have been censored in the intervention arm. This severe imbalance, despite randomization of the participants, 
introduces high risk to bias due to censoring of participants with missing follow-up data. In a hypothetical 
scenario, where individuals lost to follow-up are more likely than those who were not lost to follow up to die 
shortly after censoring, the survival benefit shown by the hazard ratio in the study is likely inflated and 
possibly inexistent. Here we would suspect a high risk of bias and, in a situation where only one study is 
included in the body of evidence or other included studies have similar imbalances , we would consider 





























































If only a survival curve and the number at risk for particular time points are available and 
direct information on the distribution of censoring is not presented (e.g. no censoring marks 
on the curves) or assessable (e.g. single marks for censoring not distinguishable on the curve 
due to high degree of censoring), it is sometimes possible to estimate the degree of 
participants censored for a certain time point by comparing the visible survival benefits in the 
curves and the number at risk for the reported time points (20). In figure 2, for example, at 
five and ten months of follow-up the same or a similar number of participants at risk are 
reported in both treatment arms (5 months: 37 versus 36; 10 months: 19 versus 19). 
Comparing this information with the visible differences in survival probabilities in the curves, 
noticeably favoring the experimental arm, allows the conclusion that substantially more 
participants have been lost to follow-up in the experimental than in the control arm. This is 
because after five and ten months of follow-up, approximately the same number of 
individuals that experienced the event (death) in the control arm must have been lost to 
follow-up in the experimental arm. Box 1 presents a detailed description of the example. 
When authors report the number of individuals for several time points together with the 
survival curves, established methods to reconstruct summary time-to-event data also allow 
approximations of the number of individuals censored within certain time intervals (11, 35). 
When authors provide the number of individuals at risk for a sufficient number of time points, 
such procedures may also conclusively support an assessment of the distribution of censoring 
in the study arms over time. Considerable variation in the overall difference and a difference 
in the distribution in terms of early versus late censoring between arms can then confirm a 
high risk of bias and a critical limitation to the effect estimator of a time-to-event outcome of 
an individual study allowing guideline authors to carefully and transparently justify their 





























































Figure 3: Kaplan-Meier curve for the outcome invasive disease-free survival from the study 
Martin et al (36) (see Box 2). The number of individuals censored up to the respective time-
points of follow-up are reported along the number of individuals at risk to experience the 
outcome at this time point. The number of censored individuals is substantially higher in the 
neratinib arm throughout the follow-up period. The number of individuals at risk (excluding 
those who experienced the event or were censored) in the placebo arm is substantially higher 
than the number of individuals at risk in the neratinib arm. Nonetheless, the neratinib arm is 
shown to be beneficial by the HR (<1). Adapted from “Neratinib after trastuzumab-based 
adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a 
randomised, double-blind, placebo-controlled, phase 3 trial” by Martin et al., 2017, The 





























































Box 2: Example 2: Martin et al. (36) 
The randomised, double blind, placebo-controlled ExteNET study compared adjuvant neratinib and placebo 
in patients with HER2-positive breast cancer after standard locoregional treatment, trastuzumab, and 
chemotherapy. The five-year analysis of the primary endpoint invasive disease-free survival which was 
defined as time from randomisation to first occurrence of invasive disease and recurrences or all cause death 
showed a significant benefit for the intervention. Hazard ratios were derived from a Cox proportional hazards 
model and individuals were censored for the primary end-point when they did not re-consent for additional 
follow-up at the date of their last physical examination, if disease recurrence did not occur within the 2 years 
of follow-up in this study or if they did not have a disease-free survival event within the relevant time-frame 
(5.6 months). In each treatment arm 1420 participants were randomized and included in the intention-to-treat 
analysis.
While the study publication did not specify the proportion of censored individuals and the respective reasons 
for censoring, the survival curve for the primary outcome (figure 3) shows severe imbalances in the number 
of censored individuals. The number of censored participants between the time-points is reported together 
with the number of participants at risk to experience the event for certain time points below the curves and 
for each study arm respectively. The percentages present the proportion of participants who are event-free for 
the respective time-points. The number of censored individuals in the experimental arm is substantially 
higher than in the placebo arm, especially in the early observational period. This results in a lower number of 
individuals is at risk, excluding those who have experienced the event of interest or were censored, at any 
time point thereafter in the favored experimental arm. Assessing the times for the beginning of accrual (July 
9, 2009), the ending of accrual (October 24, 2011) and the end of the five year follow-up (March 1, 2017) 
one can be certain that the early censoring events were due to loss to follow-up, and not to “end-of-follow-
up”, because the minimum complete observation time was at least 5.4 years (from Oct 24, 2011 - March 1, 
2017). Given the information outlined above, a judgement of high risk of bias for this study due to censoring 
of participants because of missing follow-up data is justifiable. In a hypothetical situation, where a body of 






























































6.2 What to do when individual studies do not provide the distribution of censoring over time
Review authors often find themselves in situations in which they must assess potential risk of 
bias through censoring of participants because of missing follow-up data based on only very 
limited information (16-19). When the distribution of censoring over time in individual 
studies is not clear, but there are serious imbalances in the number of individuals for whom 
data is missing (e.g. individuals lost to follow-up summarized in a study flow-diagram) in the 
study arms or the reasons for the absence of follow-up data differ among arms (e.g. provided 
in a study flow-diagram), we suggest, in accordance with the Risk of Bias 2.0 tool, concern 
for a high risk of bias (“probably yes”) for an individual study outcome (23, 24). To derive a 
decision, the instructions for risk of bias due to loss to follow-up in binary data analysis from 
the GRADE guideline on study limitations (risk of bias) should be considered (6). For time-
to-event analyses from individual studies that do not report information regarding the 
distribution of censoring over time, its degree, and reasons, we suggest explicitly stating that a 
judgement was not possible because the required information was absent.
6.3. Individual participant data would be desirable to assess the risk of bias
Within-study sensitivity analyses for censoring, such as best/worst-case scenarios and other 
imputation procedures, require individual participant data. If data on individual failure and 
censoring times and reasons are available, individual patient data meta-analyses for time-to-
event outcomes would allow for a more elaborate assessment of the sensitivity of results to 
missing data issues. 
For example, such analyses may be possible when data for individuals lost to follow-up can 
be imputed based on plausible assumptions for individuals for whom data is missing (7). 
Significant changes in the estimates could then lead to decisions to rate down the certainty of 





























































data (37) and are usually impossible to perform, when conducting a standard systematic 
review. Simple quantification measures for the completeness of follow-up in survival analyses 
also exist, but are usually not included in study reports. 
6.4. Rating the risk of bias resulting from censoring of participants because of missing follow-
up data and deriving an overall judgement for an individual study
Indicators Considerations for the risk of bias through censoring of 
participants with missing follow-up data assessment in 
individual studies
Time point of censoring considerably 
different in both arms (early versus late 
censoring)
Critical concern for high risk of bias as early censoring is more 
likely to be due to missing data (e.g. loss to follow-up) as 
opposed to end of study censoring.
Censoring degree among arms diverging 
(Overall number of censored patients 
reported, but distribution over time not 
known)
If reasons for censoring are reported (e.g. 
summarised in a study flow diagram): 
Different reasons why data for individuals 
was missing (e.g. were lost to follow-up) 
and different degree between arms.
A high risk of bias is more likely as a different degree and 
differing reasons for censoring are contradicting with a valid 
randomization process and thus imply that missingness may 
depend on the received intervention (23)
Table 1: Decision support for judgements of a risk of bias though inappropriate censoring in an 
individual study
A judgment on the risk of bias associated with missing data for time-to-event outcomes within 
GRADE should be based on the principles outlined in previous guidelines for rating the 
quality of the evidence addressing study limitations (GRADE guideline 4), particularly with 
regard to the risk of bias associated with missing participant outcome data in a body of 
evidence for both binary and continuous outcomes (GRADE guideline 17) (6, 7). The 





























































differences (e.g. censoring of individuals for whom data is missing and those who ended 
follow-up appropriately) and to support a decision on the presence of a risk of bias. 
Table 1 provides considerations that reviewers can use to estimate the extent of the risk of 
bias introduced by censoring of participants because of missing data in an individual study. 
To derive a decision on the impact of missing follow-up data on the overall risk of bias for an 
outcome in an individual study reviewers must consider all other potential study limitations 
including lack of allocation concealment or the lack of blinding following which they can 
judge risk of bias can following usual GRADE principles (6). A crucial limitation in one risk 
of bias criterion, which may include substantial differences in the degree and distribution in 
the amount of early and late censoring, or several criteria with some limitations, which may 
include considerable difference in the overall degree of censoring, may be sufficient to merit a 
judgement of a serious limitation. A crucial limitation for one or more criteria would result in 
a judgement of a very serious limitation for the outcome of an individual study (6). These 
judgements should then inform an overall rating of the GRADE risk of bias domain for a 
body of evidence. 
7. Making an overall judgement for a body of evidence
To derive a judgment for the risk of bias domain across studies in a body of evidence, 
reviewers should apply the usual GRADE principles for study imitations (6): no serious 
limitations (do not rate down), if evidence comes largely from studies at low risk of bias; 
serious limitations (rate down one level), if evidence comes largely from studies at high risk 
of bias; very serious limitations (rate down two levels), if evidence comes largely from studies 
at very high risk of bias. 
If studies vary in their risk of bias, and results differ in high and low risk of bias studies, 





























































particular, in an appropriately large set of studies, when the potential risk of bias due to 
censoring of participants with missing lost to follow-up data differs across studies, reviewers 
can conduct sensitivity analysis to determine whether results differ in high and low risk of 
bias studies. When results differ, reviewers should present best estimates from only low risk 
of bias studies.
8. Discussion and further guidance for the assessment of time-to-event evidence
For this guide we chose the prior outlined definitions and concepts, but they are not 
unassailable. Well-known resources for the conduct of systematic reviews focus on the hazard 
ratio as relative effect measure to include time-to-event data in meta-analyses (38). Therefore, 
our guidance focuses on the hazard ratio as the relative effect measure for time-to-event 
analysis. In time-to-event analysis certain competing risk analyses require censoring of 
competing events, meaning single or multiple events precluding the occurrence of the event of 
interest (13, 39). 
Nevertheless, such analyses remain susceptible to bias due to censoring of participants 
because of missing follow-up data when individuals are excluded from follow-up and 
censored for other reasons. An exception occurs when study authors applied competing risk 
analysis methods to account for the particular reasons data is absent, e.g. loss to follow-up, in 
their primary analysis. 
To illustrate the issues outlined in this guidance we present examples from randomized trials; 
some considerations are, however, also applicable to non-randomized studies with control 
arms. In the absence of randomization, confounders may introduce bias because of an 
association between censoring time and the outcome of interest and the control of such 
confounders plays a critical role (40). We acknowledge possible subsequent progress of the 





























































A great variety of additional approaches to analyze time-to-event data apply less frequently 
for primary analyses and rarely find their way into meta-analyses. Investigators have proposed 
numerous analytic techniques to test the sensitivity of single trial results to the dependence of 
censoring, several of the which are based on multiple imputation and account for the 
dependence of follow-up, taking the distribution of survival events into account. 
These approaches are not solely applicable to the Cox model, but address Kaplan-Meier 
estimators, parametric proportional hazards models and other analysis techniques. Practical 
applications of the methods show substantial bias when the survival expectation of the 
censored individuals alters in a negative or positive manner from the expectation of the 
individuals remaining on study (41-49). Computationally more advanced methods, including 
approaches that explicitly allow for adjustment of dependent censoring are based on strict 
assumptions, require detailed data, and are currently used only for exploratory purposes. 
When the results of such procedures are available they can support a judgement on the 
consequences of censoring (50-52). 
Because the occurrence of adverse events is usually carried out as binary data analysis in 
contingency tables, censoring is an important threat to the validity of safety analyses. 
However, when comparing adverse events among study arms, all individuals should be 
observed for a similar time-period to allow a fair comparison of interventions. Censoring of 
participants from individual study arms, for example because of competing events such as 
switching treatment after disease progression, results in varying observation times among 
participants and subsequently in diverging average times at risk for adverse events. Bender et 
al. (53) pointed out specific situations in which the risk of bias due to inadequate analysis of 
adverse events led to significant reductions of the certainty in the evidence in evaluations to 





























































harm could not be excluded with sufficient certainty”. Analysis of safety endpoints by means 
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Appendix A1: Independent and non-informative censoring
Non-informative censoring, as described by Lagakos (15), requires “that the time-point of a 
censoring event holds no information about an individual’s likelihood to experience the event 
of interest (its survival time)”. This means that the true distribution of the survival time, where 
no individual is lost from observation and individuals are observed until the event occurs, and 
the true censoring distribution, where the study ends before all subjects experience the event 
and censored individuals do not experience the event prior to the end of study, provide no 
information for each other. Informative censoring is sometimes referred to as a type of 
selection bias under the reasoning that loss to follow-up or withdrawal in randomized trials 
leads to selection after randomization, when certain participants due to certain measured or 
unmeasured characteristics or conditions may be less likely or more likely to be censored and 
as well less likely or more likely to experience the event of interest. In other words, the 
association of the risk of being censored and the risk of experiencing the event results from a 
common source of both risks (40). The definition of independent censoring is not equivalent 
to non-informative censoring and Lagakos (15) shows that dependent censoring is a special 
form of informative censoring, however, in most situations where the assumption of 





























































Appendix A2: Reporting requirements for survival analysis that allow to assess the risk of 
bias due to censoring
In order to assess the suitability of the independent censoring assumption by users, including 
systematic review and guideline authors, the methods in a primary study report should ideally 
provide detailed definitions of the assessed outcomes including the event(s) of interest, the 
time of origin and all conditions leading to censoring despite end-of observation (e.g. absence 
of the event at study closure, loss to follow-up or withdrawal due to competing events) (17, 
18). Standardized outcome definitions would here be highly preferable (19). With regard to 
the applied analysis methods we would demand that it is explicitly reported why the 
assumption of dependent censoring is feasible. When outcomes which include competing 
risks are assessed, we would require the application and reporting of appropriate methods, 
which will be outlined in a future guidance. The result section should hold the total events of 
interest and number of censored individuals in each of the study arms and the number of 
participants censored separately of those before the end the observational period including the 
individual reasons (17, 18). It is highly desirable that Kaplan-Meier curves, if feasible, are 
given for each of the assessed outcomes. In the curves, the time-points of censored events 
should be indicated as well as the number at risk below the curves for appropriate time-points 
(22). The number of censored individuals for certain time-points with an indication of 
censoring reasons is an option to enhance transparency. Lastly, the duration of follow-up for 





























































Appendix A3. Reconstruction of survival data to illustrate the impact of early dependent 
censoring
To illustrate the impact of early dependent censoring on comparisons, we reconstructed 
individual participant data from the survival curves published for the analysis of overall 
survival in the article by Denis et al. (32). The study shows an unbalanced number of 
censored participants particularly during early follow-up, with more censored participants in 
the intervention arm compared to the control arm. Given the clear reporting in the survival 
curves, we were able to reconstruct outcome event and censoring time points for the 
individuals in each of the compared groups. We verified our proceeding with the algorithm 
presented Guyot et al. (33) that allows to reconstruct individual participant level data from 
published survival curves. The algorithm attributes a constant rate of censoring to intervals in 
between outcome events and time-points for which a number of individuals at risk is reported. 
It therefore works optimal assuming independent censoring. Under the objective of our 
illustration, we decided not to directly use the dataset resulting from the algorithm proposed 
by Guyot and colleagues but to work with individual patient data that we reconstructed 
directly from the published survival curve. Nevertheless, we used the data set produced under 
application of the algorithm to confirm the consistency of our manually extracted data by 
comparing the data points retrieved through both approaches. 
We extracted data with the software DigitizeIt (www.digitizeit.de), which allows to assign 
each point on the survival curve a corresponding time-point on the x-axis. We marked all 
declines of the curve as outcome event and all crosses as censoring time-points. The reported 
curve for the experimental arm was unclear for two censoring events in the first interval (0 to 
5 months) and the last interval (over 15 months) respectively, which were not directly 
identifiable on the curve, but must have occurred in these intervals as indicated by the number 





























































censoring events were not identifiable within the first interval (0 to 5 months). For all 
scenarios we assumed the missing censoring events to have happened on the last possible 
time-point of this interval (4.99 and 18.99 months). In the so retrieved dataset, we modified 
the survival data of participants censored within the first seven months of follow-up to 
illustrate the impact of early dependent censoring. We present a hypothetical scenario where 
all participants censored prior to seven months of follow-up experience the outcome event one 
month after the original censoring. Subsequently, we calculated hazard ratios with the Cox 
proportional hazards model and present Kaplan-Meier survival curves. All statistical analyses 
were performed using the software R (56). We want to point out that our imputation does not 
claim to compare a difference in treatment effects, but to illustrate the loss of certainty that is 
introduced to survival analyses through a high degree of censoring particularly during the 





























































Appendix A4. Reconstructed survival curves
Appendix-figure 1: Kaplan-Meier survival curves calculated from the individual participant level 
data reconstructed from the analysis of overall survival in Denis et al. (32). 
Appendix-figure 2: Kaplan-Meier survival curve calculated from the individual participant level 
data reconstructed from the analysis of overall survival in Denis et al. (32). Participants who 
were censored prior to seven months of follow-up in both study arms were set to experience the 
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